Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
30 November 2017
E-007368-17
Question for written answer
to the Commission
Rule 130
Urmas Paet (ALDE)

 Subject:  Availability and price of cancer drugs
 Answer(s) 

There are problems with the availability and expensiveness of cancer drugs in many EU Member States: modern medicines are expensive and countries’ insurance systems for pharmaceuticals cannot provide them in sufficient quantities. What will the Commission do to help Member States to provide better support for cancer patients and keep the prices of new medicines under control? How could the Commission contribute to the diversification of pharmaceutical companies, in order to bring prices down and make it possible to reduce the number of monopolies? Does the Commission consider it worthwhile to analyse the current patent system and possible changes to it, given that part of investment in the development of new medicines has been funded by public research programmes?

Original language of question: ET 
Last updated: 14 December 2017Legal notice